Citation Impact
Citing Papers
Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2
2011 Standout
Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice
2007 StandoutNobel
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
2013
The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism
2013 Standout
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
2002
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
2004
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum
2003
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure
2004
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
2016
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
2006
Cholecystokinin Receptor Family
1994
Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor
2006
Microbial tryptophan catabolites in health and disease
2018 Standout
Insulinotropic Hormone Glucagon-Like Peptide-1-(7–37) Appears Not to Augment Insulin-Mediated Glucose Uptake in Young Men during Euglycemia1
1998
Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers
2002
The gut microbiota, bacterial metabolites and colorectal cancer
2014 Standout
Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1
1998
The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction
2001
The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
2006
Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics
2017 Standout
The Human Intestinal Microbiome in Health and Disease
2016 Standout
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
1999
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans
1998
The biology of incretin hormones
2006 Standout
Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)
2007
Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
2001
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
2002
Classification and functions of enteroendocrine cells of the lower gastrointestinal tract
2011
Ghrelin Stimulates Gastric Acid Secretion and Motility in Rats
2000
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
2005
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
1998
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Biology of Incretins: GLP-1 and GIP
2007 Standout
Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients
2001
The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum
2002
The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
2000
Glucagon-like peptide-1 is a physiological incretin in rat.
1995
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Type 2 diabetes
2017 Standout
Glucagon-like peptide 1(GLP-1) in biology and pathology
2005
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
2017 StandoutNobel
Lipolytic action of glucagon-like peptides in isolated rat adipocytes
1992
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Free fatty acid receptor 2 and nutrient sensing: a proposed role for fibre, fermentable carbohydrates and short-chain fatty acids in appetite regulation
2010
Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice
2003
Neural regulation of glucagon-like peptide-1 secretion in pigs
2004
Ileal release of glucagon-like peptide-1 (GLP-1)
1995
Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans
1997
GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics
2003
Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus
1995 Standout
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
2002
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
1996
The Physiology of Glucagon-like Peptide 1
2007 Standout
The Discovery and Development of Liraglutide and Semaglutide
2019
Gut hormones and diabetes mellitus
1992
Secretion of Proglucagon-Derived Peptides in Response to Intestinal Luminal Nutrients*
1991
The gut microbiota — masters of host development and physiology
2013 Standout
Short-chain fatty acids in control of body weight and insulin sensitivity
2015 Standout
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter
2004
Obesity and the Regulation of Energy Balance
2001 Standout
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Glucagonlike peptide 1: A newly discovered gastrointestinal hormone
1994
Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes
2003
Insights into bombesin receptors and ligands: Highlighting recent advances
2015
Ghrelin: Structure and Function
2005 Standout
Glucagon-Like Peptide-1 7-36 Amide and Peptide YY from the L-Cell of the Ileal Mucosa Are Potent Inhibitors of Vagally Induced Gastric Acid Secretion in Man
1994
The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem
2005
Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy
1991
Glucagon-Like Peptide-1 7-36 Amide and Peptide YY Have Additive Inhibitory Effect on Gastric Acid Secretion in Man
1997
Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide
1995
The major glucagon-like peptide-1 metabolite, GLP-1-(9–36)-amide, does not affect glucose or insulin levels in mice
2004
Incretins, insulin secretion and Type 2 diabetes mellitus
2004
Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2
1994
A role for glucagon-like peptide-1 in the central regulation of feeding
1996 StandoutNature
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
1993 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
1992
Gut microbiota in human metabolic health and disease
2020 Standout
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
1998
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
2016
Intestinal Microbiota During Infancy and Its Implications for Obesity
2009
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
2010
Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes
2004
Fluorine in medicinal chemistry
2007 Standout
Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas
1996
Can Gut Hormones Control Appetite and Prevent Obesity?
2008
Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum
2000
Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.
1992
Glucagon-Like Peptide-1-(7–36) Amide and Peptide YY Mediate Intraduodenal Fat-Induced Inhibition of Acid Secretion in Dogs*
1998
Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
1999
Oxyntomodulin Inhibits Food Intake in the Rat
2001
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects
2002
Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
1999
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
2001
A Preprandial Rise in Plasma Ghrelin Levels Suggests a Role in Meal Initiation in Humans
2001 Standout
Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
2000
Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control
2001
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials
2016
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.
1995
Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
1996
The Many Roles for Fluorine in Medicinal Chemistry
2008 Standout
Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
1998
Incretin hormones - an update
2001
1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties
2003
Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration
2000
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
2004
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
1996
Complete Sequences of Glucagon-like Peptide-1 from Human and Pig Small Intestine
1989
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
2014
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
1997
Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes
1998
Proglucagon processing in porcine and human pancreas.
1994
A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis
2004
Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential
1999
Diabetic Neuropathies
2001
Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
1997
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.
1997
Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats
1994
Neural contribution to the effect of glucagon-like peptide-1-(7—36) amide on arterial blood pressure in rats
1999
Ghrelin Enhances Appetite and Increases Food Intake in Humans
2001 Standout
The Glucagon-Like Peptides
1999
Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
2012 Standout
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
2016 Standout
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
2002
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Diabetic Autonomic Neuropathy
2003 Standout
Glucagon-like peptide-1, a new hormone of the entero-insular axis
1992
The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity
1998 Standout
Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids
1999
Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate
2003
Glucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
2003
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in Mice*
2000
Asymmetric Enamine Catalysis
2007 StandoutNobel
Gut hormone PYY3-36 physiologically inhibits food intake
2002 StandoutNature
ENTEROGLUCAGON
1997
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
1995
Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects
2005
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
2003
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
2005
Works of Birgit Schjoldager being referenced
GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans
1989
Oxyntomodulin from distal gut
1989
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
1993
Effect of Pancreatic Glucagon and Its 1-21 Fragment on Gastric Emptying in Man
1988
Functional and biochemical characterization of the human gallbladder muscularis cholecystokinin receptor
1989
Gastrin-releasing peptide is a transmitter mediating porcine gallbladder contraction
1991
Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man
1988